Henry Schein’s (HSIC) Neutral Rating Reaffirmed at Goldman Sachs Group

Share on StockTwits

Goldman Sachs Group reissued their neutral rating on shares of Henry Schein (NASDAQ:HSIC) in a report released on Friday.

Several other brokerages have also commented on HSIC. Craig Hallum raised their price objective on Henry Schein from $83.00 to $96.00 and gave the company a buy rating in a report on Tuesday, August 7th. Zacks Investment Research raised Henry Schein from a hold rating to a buy rating and set a $85.00 price objective on the stock in a report on Tuesday, July 10th. BidaskClub lowered Henry Schein from a buy rating to a hold rating in a report on Friday, August 10th. Morgan Stanley lifted their price target on Henry Schein from $65.00 to $66.00 and gave the stock an underweight rating in a research note on Tuesday, October 9th. Finally, Leerink Swann set a $100.00 price target on Henry Schein and gave the stock a buy rating in a research note on Tuesday, August 7th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $83.83.

HSIC traded down $0.78 during trading on Friday, hitting $82.51. The company’s stock had a trading volume of 1,337,183 shares, compared to its average volume of 1,662,988. The company has a current ratio of 1.29, a quick ratio of 0.68 and a debt-to-equity ratio of 0.34. Henry Schein has a twelve month low of $62.56 and a twelve month high of $90.52. The firm has a market cap of $12.75 billion, a P/E ratio of 22.92, a PEG ratio of 2.40 and a beta of 0.97.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Monday, August 6th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. Henry Schein had a return on equity of 20.40% and a net margin of 3.15%. The company had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.31 billion. During the same period last year, the company earned $0.88 earnings per share. Henry Schein’s quarterly revenue was up 8.7% compared to the same quarter last year. Equities research analysts forecast that Henry Schein will post 4.12 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. NEXT Financial Group Inc acquired a new position in Henry Schein during the third quarter worth $103,000. McAdam LLC acquired a new position in Henry Schein during the third quarter worth $104,000. Squar Milner Financial Services LLC acquired a new position in Henry Schein during the second quarter worth $120,000. Piedmont Investment Advisors LLC acquired a new position in Henry Schein during the second quarter worth $130,000. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in Henry Schein by 57.1% during the second quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock worth $160,000 after buying an additional 800 shares during the last quarter.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Recommended Story: Why is the conference call important?

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Virtus Investment Partners Inc  Stake Lowered by JPMorgan Chase & Co.
Virtus Investment Partners Inc Stake Lowered by JPMorgan Chase & Co.
Brokerages Set ADO Properties SA  PT at $54.48
Brokerages Set ADO Properties SA PT at $54.48
Sleep Number Corp  Shares Sold by JPMorgan Chase & Co.
Sleep Number Corp Shares Sold by JPMorgan Chase & Co.
Staffing 360 Solutions   Shares Down 9%
Staffing 360 Solutions Shares Down 9%
Axovant Sciences  Stock Price Down 27.5%
Axovant Sciences Stock Price Down 27.5%
9,516 Shares in MSB Financial Corp.  Purchased by Northern Trust Corp
9,516 Shares in MSB Financial Corp. Purchased by Northern Trust Corp


© 2006-2018 Ticker Report